Anti-TAT 113 antibodies

Details Anti-TAT 113 antibodies Anti-TAT 113 antibodies

2007-11-20

2009-06-16

Blanchard, David J. (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C424S133100, C424S141100, C424S155100, C424S181100, C435S069600, C435S070210, C530S387300, C530S388800, C530S391700

Reexamination Certificate

active

07547768

ABSTRACT:
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

REFERENCES:
patent: 2005/0107595 (2005-05-01), Cairns et al.
patent: 0 284 362 (1988-09-01), None
patent: 0 875 569 (1998-04-01), None
patent: 1 111 048 (2001-06-01), None
patent: WO 98/37193 (1998-08-01), None
patent: WO 99/09166 (1999-02-01), None
patent: WO 99/33869 (1999-07-01), None
patent: WO 00/12702 (2000-03-01), None
patent: WO 00/15666 (2000-03-01), None
patent: WO 00/55633 (2000-09-01), None
patent: WO 01/18046 (2001-03-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 01/46261 (2001-06-01), None
patent: WO 01/51633 (2001-07-01), None
patent: WO01/94629 (2001-12-01), None
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/30268 (2002-04-01), None
patent: WO02/064798 (2002-08-01), None
patent: WO 02/064798 (2002-08-01), None
patent: 03/000113 (2003-01-01), None
patent: WO03/000113 (2003-01-01), None
patent: WO03/043631 (2003-05-01), None
patent: WO 03/043631 (2003-05-01), None
patent: 2005/117986 (2005-12-01), None
patent: WO 2006/010496 (2006-02-01), None
patent: WO2006/010496 (2006-02-01), None
Lederman et al. Molecular Immunology 28:1171-1181, 1991.
Li et al. Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980.
Fundamental Immunology, William E. Paul, M.D. ed., 3rd ed., p. 242, 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79(6):1979-1983, Mar. 1982.
Colman P. M. Research in Immunology, 145:33-36, 1994.
Bendig M. M. Methods: A Companion to Methods in Enzymology, 8:83-93, 1995.
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Blast Report Assession No. AX775590 . Record created Jul. 9, 2003.
Blast Report Assession No. BC017023 . Record created Jul. 15, 2006.
Blast Report Assession No. BT006664 . Record created May 13, 2003.
Blast Report Assession No. DD106754 . Record created Nov. 4, 2005.
Burger, A M et al., “Identification and characterization of prostein, a novel prostate-specific protein”, Cancer Research, American Association for Cancer Research, Baltimore, MS, US, vol. 61, No. 4 (Feb. 15, 2001), pp. 1563-1568 XP002262454 ISSN: 0008-5472.
Lopez, M et al., “Nectin2alpha (PRR2alpha or HveB) and Nectin2delta are low-efficiency mediators for entry of herpes simplex virus mutants carrying the Leu25Pro substitution in glycoprotein D” Journal of Virology, The American Society for Microbiology, US, vol. 74, No. 3 (Feb. 2000) pp. 1267-1274, XP002301423 ISSN: 0022-538X.
Lopez, M et al., “The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule” Blood, W. B. Saunders Company, Orlando, FL, US., vol. 92, No. 12 (Dec. 15, 1998), pp. 4602-4611 XP002268761 ISSN: 0006-4971.
Warner, M S et al., “A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus” Virology, Academic Press, orlando, US, vol. 246, No. 1 (Jun. 20, 1998), pp. 179-189, XP004445786 ISSN: 0042-6822.
Xu, J et al., “Identification and characterization of prostein,a novel prostate-specific protein” Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 61, No. 4 (Feb. 15, 2001), pp. 1563-1568, XP002262454 ISSN: 0008-5472.
Fujimoto, N et al., “Expressing of microfibril-associated glycoprotein-1 (MAGP-1) in human epidermal keratinocytes”, Archives of Dermatological Research, vol. 292, No. 1 (Jan. 2000) pp. 21-26 XP002436049 ISSN: 0340-3696.
Zebda, N et al., “Expression of PNA-binding sites on specific glycoproteins by human melanoma cells is associated with a high metastatic peotential”, Journal of Cellular Biochemistry, vol. 54, No. 2 (1994) pp. 161-173 XP002436050 ISSN: 0730-2312.
Database EMBL [Online] Nov. 14, 2001, Homo Sapiens Dipeptidase 1 (Renal), mRNA (cDNA Clone MGC:8990 IMAGE:3846046), Complete CDS:, XP002406227 retrieved from EBI Accession No. EMBL:BC01703, Database Accession No. BC017023.
Database EMBL [Online] May 15, 2003, “Homo Sapiens Dipeptidas 1 (Renal) mRNA, Complete CDS”, XP002406228 retrieved from EBI Accession No. EMBL: BT006664 Database Accession No. BT006664.
Database EMBL [Online] Nov. 25, 2005, “Compositions and Methods for the Diagnosis and Treatment of Tumor” XP002406229 retrieved from EBI Accession No. EM—PAT:DD106754, Database Accession No. DD106754.
Database EMBL [Online] Jul. 9, 2003, “Sequence 6 from Patent WO03043631” XP002406413 retireved from EBI Accession No. EM—PAT:AX775590 Database Accession No. EM—PAT:AX775590.
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy”Nature Biotechnology21:778-784 (2003).
Doronina, S., et al., “Immunoconjugates Comprised of Drugs with Impaired Cellular Permeability: A New Approach to Targeted Therapy”Abstracts of Papers American Chemical Society228 (Part 1) :U908 (Aug. 2004).
Henderson, M., et al., “Microfibril-associated Glycoprotein-1 (MAGP-1) Is Specifically Located on the Beads of the Beaded-filament Structure for Fibrillin-containing Microfibrils as Visualized by the Rotary Shadowing Technique”The J. Of Histochemistry and Cytochemistry44(12): 1389-97 (1996).
Mannion, B., et al., “The Light Chain of CD98 Is Identified as E16/TA1 Protein”The J. of Biological Chemistry273 (50) :33127-29 (Dec. 11, 1998).
Alberts, et alMolecular Biology of the Cell, 3rd edition edition pp. 465 (1994).
Fu et alEMBO Journal15:4392-4401 (1996).
Hanash S., “Integrated global profiling of cancer”Nature Reviews, Applied Proteomics Collectionpp. 9-14 (Mar. 2005).
Hu, et al.Journal of Proteome Research2:405-412 (2003).
Powell et al., “Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype”Pharmacogenesis(abstract) 8(5) :411-421 (Oct. 1998).
Vallejo et al., “Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression”Biochimie(abstract) 82(12) :1129-1133 (Dec. 2000).
Blast Results A-1—A-248 (Feb. 27, 2003).
Blast Results B1—B17 (Nov. 5, 2001).
Database Netaffx [Online] Affymetrix; Hu35KsubC, HuksubD—Oct. 17, 2008—XP002500551 retrieved from https://www.affymetrix.com/analysis
etaffx Abstract.
Database Netaffx [Online] Affymetrix; Array Hu6800 has DPEP1—Oct. 22, 2007—XP002500695 retrieved from https://www.affymetrix.com/analysis
etaffx Abstract.
Buckhaults, P., et al.,Cancer Research—61:6996-7001 (2001).
McDoniels-Silvers, M.L., et al.,Proceedings of the Annual Meeting of the American Association for Cancer Research—41(680):680 (2000).
Müller, H., et al.,Genes&Development—15(3):267-285 (2001).
Ono, K., et al.,Cancer Research—60(18):5007-5011 (2000).
Perou, C.M., et al.,Proceedings of the National Academy of Sciences of USA—96(1):9212-9217 (1999).
Ross, D.T., et al.,Nature Genetics—24:227-235 (2000).
Schweinfest, C.W., et al.,Gene Analysis Techniques—7:64-70 (1990).
Wang, T., et al.,Oncogene—19(12):1519-1528 (2000).

Affiliated with

Also associated with

Rating

Anti-TAT 113 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-TAT 113 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-TAT 113 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4128340